Injectafer (Ferric Carboxymaltose Injection)
Brand Names: Injectafer
Methodology & AI Transparency ⓘ
Injectafer (Ferric Carboxymaltose Injection) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Injectafer (Ferric Carboxymaltose Injection) represents a prescription brand-name parenteral iron replacement entry registered by American Regent, Inc.
- 2 Real-world patient consensus: Branded parenteral iron replacement presentation of Ferric Carboxymaltose Injection (American Regent, Inc.); generic reference RxCUI RXN-B05170650.
- 3 Typical cash cost range: Dispensing cost comparison spans $447.48 mail/discount cash up to $1185.82 uninsured retail (federal NADAC $6.0970).
- 4 Top reported side effects / signs: Most commonly reported Injectafer (Ferric Carboxymaltose Injection) tolerability events: nausea (9.3%), headache (8.6%), dizziness (5.8%).
Ask our AI Specialists anything about Injectafer (Ferric Carboxymaltose Injection)
Injectafer (Ferric Carboxymaltose Injection) Mechanism, CYP450 Pathways & DailyMed Monograph
Injectafer (Ferric Carboxymaltose Injection) represents a prescription brand-name parenteral iron replacement entry registered by American Regent, Inc. with package codes 0517-0650, 0517-0620. Reviewed against 2026-07-01 FDA SPL standards (50 mg/mL Injection, Solution; 50 mg/mL), clinical deployment addresses Clinicians prescribe Ferric Carboxymaltose Injection (50 mg/mL Injection, Solution; NDC 0781-3542, 0517-0650) as a.
Injectafer achieves therapeutic action via Ferric Carboxymaltose Injection, engaging parenteral iron replacement physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 50 mg/mL Injection, Solution; 50 mg/mL (registered by American Regent, Inc., NDC 0517-0650, 0517-0620), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Injectafer ($1185.82 retail) with generic Ferric Carboxymaltose Injection ($447.48 low cash).
Clinical clearance of Injectafer (Ferric Carboxymaltose Injection) (Parenteral Iron Replacement) relies on dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of injectafer (ferric carboxymaltose injection) with a Mean elimination half-life of 7 to 14 hours across adult Injectafer (Ferric Carboxymaltose Injection) dosing half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Injectafer (Ferric Carboxymaltose Injection) (50 mg/mL Injection, Solution) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after injectafer (ferric carboxymaltose injection) administration.
FDA clinical labeling for Injectafer (Ferric Carboxymaltose Injection) restricts administration in contraindicated in patients with prior serious allergic response to injectafer (ferric carboxymaltose injection) (ndc 0517-0650); severe baseline organ impairment where ferric carboxymaltose injection accumulation exceeds safe therapeutic margins across 50 mg/mL Injection, Solution, 50 mg/mL, with self-reported patient tracking dominated by nausea (9.3% of reports), headache (8.6% of reports), dizziness (5.8% of reports).
Separate Injectafer (Ferric Carboxymaltose Injection) ingestion from mineral supplements or antacids to preserve gastrointestinal bioavailability.
Reconcile eGFR-adjusted medications before escalating Injectafer (Ferric Carboxymaltose Injection) in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Injectafer (Ferric Carboxymaltose Injection) (NDC 0517-0650)
- Severe baseline organ impairment where Ferric Carboxymaltose Injection accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (10 Reports)
Injectafer (Ferric Carboxymaltose Injection) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Injectafer (Ferric Carboxymaltose Injection))
Human clinical trial evidence for Injectafer (Ferric Carboxymaltose Injection) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Injectafer (Ferric Carboxymaltose Injection) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $6.0970/unit (~$182.91/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1185.82 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $447.48 / mo | View logs ↓ |
Injectafer (Ferric Carboxymaltose Injection) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Injectafer (Ferric Carboxymaltose Injection) RxNorm Concept ID | RXN-B05170650 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $6.0970 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1185.82 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $447.48 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 81.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Injectafer (Ferric Carboxymaltose Injection) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Injectafer (Ferric Carboxymaltose Injection) (parenteral iron replacement) monograph synthesizing RxNorm RXN-B05170650, openFDA FAERS signals, and $447.48–$1185.82 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Injectafer (Ferric Carboxymaltose Injection) community threads and patient logs by age, biological sex, dosage, and treatment duration.